Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate

References

• Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–11. doi:10.1016/S0140-6736(17)33293-2.
   PubMed Web of Science ®Google Scholar
• Dao CN, Kamimoto L, Nowell M, Reingold A, Gershman K, Meek J, Arnold K, Farley M, Ryan P, Lynfield R, et al. Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2008 seasons in the United States. J. Infect Dis. 2010; 202:881–88. doi:10.1086/655904.
   PubMed Web of Science ®Google Scholar
• Choi WS, Cowling BJ, Noh JY, Song JY, Wie SH, Lee JS, Seo YB, Lee J, Jeong HW, Kim YK, et al. Disease burden of 2013-2014 seasonal influenza in adults in Korea. PLoS One. 2017;12:e0172012. doi:10.1371/journal.pone.0172012.
   PubMed Web of Science ®Google Scholar
• Behrouzi B, Bhatt DL, Cannon CP, Vardeny O, Lee DS, Solomon SD, Udell JA. Association of influenza vaccination with cardiovascular risk: a meta-analysis. JAMA Netw. Open. 2022;5:e228873. doi:10.1001/jamanetworkopen.2022.8873.
   PubMedGoogle Scholar
• Center of Disease Control and Prevention. Flu vaccination. Updated 2022 Sep 6. [Accessed Mar 27, 2023]. https://www.cdc.gov/flu/highrisk/heartdisease.htm.
   Google Scholar
• Center of Disease Control and Prevention. Flu vaccine recommendation in COVID-19 outbreak. Updated 2021 Apr 15. [Accessed Mar 27, 2023]. https://www.cdc.gov/vaccines/pandemic-guidance/index.html.
   Google Scholar
• World Health Organization. Types of seasonal flu vaccines. Updated 2010 May 13. [Accessed Mar 27, 2023]. https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/vaccination/types-of-seasonal-influenza-vaccine.
   Google Scholar
• Choi WS, Choi JH, Kwon KT, Seo K, Kim MA, Lee SO, Hong YJ, Lee J-S, Song JY, Bang JH, et al. Revised adult immunization guideline recommended by the Korean society of infectious diseases, 2014. Infect Chemother. 2015;47(1):68–79. doi:10.3947/ic.2015.47.1.68.
   PubMed Web of Science ®Google Scholar
• Choi EJ, Park JH, Chun BC. Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea. Vaccine. 2020;38(32):5002–08. doi:10.1016/j.vaccine.2020.05.065.
   PubMed Web of Science ®Google Scholar
• Organisation for Economic Co-operation and Development. OECD health statistics 2019. [Accessed Mar 27, 2023]. https://www.oecd-ilibrary.org/sites/2700bb99-en/index.html?itemId=/content/component/2700bb99-en.
   Google Scholar
• Yun JW, Noh JY, Song JY, Chun C, Kim Y, Cheong HJ. The Korean influenza national immunization program: history and present status. Infect Chemother. 2017;49(4):247–54. doi:10.3947/ic.2017.49.4.247.
   PubMed Web of Science ®Google Scholar
• Park M, Wu P, Goldstein E, Kim WJ, Cowling BJ. Influenza-associated excess mortality in South Korea. Am. J. Prev. Med. 2016;50(4):e111–e9. doi:10.1016/j.amepre.2015.09.028.
   PubMedGoogle Scholar
• Kissling E, Rondy M. Early 2016/17 vaccine effectiveness estimates against influenza A (H3N2): i-MOVE multicentre case control studies at primary care and hospital levels in Europe. Eurosurveillance. 2017;22:30464. doi:10.2807/1560-7917.ES.2017.22.7.30464.
   Web of Science ®Google Scholar
• Hollingsworth R, Palmu A, Pepin S, Dupuy M, Shrestha A, Jokinen J, Syrjänen R, Nealon J, Samson S, De Bruijn I, et al. Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: rationale and design of a real-world pragmatic randomized clinical trial. Am. Heart J. 2021;237:54–61. doi:10.1016/j.ahj.2021.03.007.
   PubMed Web of Science ®Google Scholar
• Center of Disease Control and Prevention. Preference for specific flu vaccines for seniors. Updated 2022 June 30. [Accessed Mar 26, 2023]. https://www.cdc.gov/media/releases/2022/s0630-seniors-flu.html.
   Google Scholar
• Cheong HJ. Cost-effectiveness analysis of extension of influenza immunization program. 2020.
   Google Scholar
• United States Department of Veterans Affairs. Decision analysis: decision trees, simulation models, sensitivity analyses. Updated 2021 Mar 19. [Accessed Mar 27, 2023]. https://www.herc.research.va.gov/include/page.asp?id=decision-analysis.
   Google Scholar
• Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, Teerawattananon Y, Asfaw E, Lopert R, Culyer AJ, et al. The international decision support initiative reference case for economic evaluation: an aid to thought. Value Health. 2016;19(8):921–28. doi:10.1016/j.jval.2016.04.015.
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL, et al. Economic analysis of vaccination programs: an ISPOR good practices for outcomes research task force report. Value Health. 2018;21(10):1133–49. doi:10.1016/j.jval.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Redondo E, Drago G, Lopez-Belmonte JL, Guillen JM, Bricout H, Alvarez FP, Callejo D, Gil de Miguel Á. Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine. Vaccine. 2021;39(36):5138–45. doi:10.1016/j.vaccine.2021.07.048.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N. Engl. J. Med. 2014;371(7):635–45. doi:10.1056/NEJMoa1315727.
   PubMed Web of Science ®Google Scholar
• Ahn. Development of reasonable Korean evaluation criteria for osteoporosis. [Accessed Mar 27, 2023]. https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=20. [ Korean].
   Google Scholar
• Yun. Cost-effetiveness of influenza vaccine strategies for the elderly in South Korea. PLoS One. 2019 Jan 25;14(1):e0209643. doi:10.1371/journal.pone.0209643.
   PubMed Web of Science ®Google Scholar
• Korean Statistics Information Service. e national indicators - exchange rates. [Accessed Mar 27, 2023]. https://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=1068123.
   Google Scholar
• Korean Statistics Information Service. Residence statistics. [Accessed Apr 25, 2022]. https://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B04006&conn_path=I2.
   Google Scholar
• Korean Statistics Information Service. Complete life table. [Accessed Apr 25, 2022]. https://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B42&conn_path=I2.
   Google Scholar
• Korean Disease Control and Prevention Agency. Vaccine coverage rates - provided by KDCA. [Accessed Apr 25, 2022]. https://www.open.go.kr/com/main/mainView.do?mainBgGubun=search.
   Google Scholar
• Somes MP, Turner RM, Dwyer LJ, Newall AT. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: a systematic review and meta-analysis. Vaccine. 2018;36(23):3199–207. doi:10.1016/j.vaccine.2018.04.063.
   PubMed Web of Science ®Google Scholar
• Lee JKH, Lam GKL, Shin T, Kim J, Krishnan A, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert. Rev. Vaccines. 2018;17:435–43. doi:10.1080/14760584.2018.1471989.
   PubMed Web of Science ®Google Scholar
• Safety and immunogenicity of high-dose quadrivalent influenza vaccine in participants ≥65 years in the US. [Accessed Jun 12, 2023]. https://classic.clinicaltrials.gov/ct2/show/NCT03282240.
   Google Scholar
• Health Insurance Review and Assessment Service. Guidelines for the economic evaluation of drugs. Updated 2021 Mar 15. [Accessed Mar 27, 2023]. https://www.hira.or.kr/ebooksc/ebook_630/ebook_630_202103150917443810.pdf.
   Google Scholar
• Health Insurance Review and Assessment Service. Drug reimbursement price ceiling table. [Accessed Mar 27, 2023]. https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000.
   Google Scholar
• Korean Disease Control and Prevention Agency. Vaccination costs in accordance with the regulations on entrustment of vaccination services (KDCA 2021–98). [Accessed Sep 15, 2023]. https://www.kdca.go.kr/filepath/boardSyview.es?bid=0017&list_no=712672&seq=1.
   Google Scholar
• Health Insurance Review and Assessment Service. Weighted average drug cost table. [Accessed Mar 27, 2023]. https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030017000000.
   Google Scholar
• Health Insurance Review and Assessment Service. Fee-for-service price 2021. [Accessed Oct 19, 2022]. https://www.hira.or.kr/npay/index.do.
   Google Scholar
• Korean Statistics Information Service. Consumer price index. [Accessed Apr 25, 2022]. http://kostat.go.kr/incomeNcpi/cpi/index.action.
   Google Scholar
• Korean Disease Control and Prevention Agency. National health statistics. [Accessed Mar 27, 2023]. https://knhanes.kdca.go.kr/knhanes/sub04/sub04_04_01.do.
   Google Scholar
• Yun JW, Choi MJ, Shin GS, Lim JO, Noh JY, Kim YK, Song JY, Kim WJ, Choi S-E, Cheong HJ, et al. Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea. PLoS One. 2019;14:e0209643. doi:10.1371/journal.pone.0209643.
   PubMed Web of Science ®Google Scholar
• Becker DL, Chit A, DiazGranados CA, Maschio M, Yau E, Drummond M. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors. Hum. Vaccines Immunother. 2016;12:3036–42. doi:10.1080/21645515.2016.1215395.
   PubMed Web of Science ®Google Scholar
• Colrat F, Thommes E, Largeron N, Alvarez FP. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: a systematic literature review. Vaccine. 2021;39(Suppl 1):A42–a50. doi:10.1016/j.vaccine.2020.12.036.
   PubMedGoogle Scholar
• van Aalst R, Russo EM, Neupane N, Mahmud SM, Mor V, Wilschut J, Chit A, Postma M, Young-Xu Y. Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US veteran population: estimating the impact on hospitalization cost for cardio-respiratory disease. Vaccine. 2019;37:4499–503. doi:10.1016/j.vaccine.2019.06.066.
   PubMed Web of Science ®Google Scholar
• Chit A, Roiz J, Briquet B, Greenberg DP. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. Vaccine. 2015;33:734–41. doi:10.1016/j.vaccine.2014.10.079.
   PubMed Web of Science ®Google Scholar
• Center of Disease Control and Prevention. Seasonal influenza vaccine effectiveness. Updated 2020 Dec 22. [Accessed Oct 6, 2022]. https://www.cdc.gov/flu/vaccines-work/2019–2020.html.
   Google Scholar
• Public Health England. Influenza vaccine effectiveness: seasonal estimates. Updated 2018 Jul 18. [Accessed Oct 6, 2022]. https://www.gov.uk/government/publications/influenza-vaccine-effectiveness-seasonal-estimates.
   Google Scholar
• Meng Z, Zhang J, Shi J, Zhao W, Huang X, Cheng L, Yang X. Immunogenicity of influenza vaccine in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness. Hum. Vaccines Immunother. 2020;16:2680–89. doi:10.1080/21645515.2020.1747375.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2022-23 influenza season. MMWR Recomm. Rep. 2022;71:1–28. doi:10.15585/mmwr.rr7101a1.
   PubMed Web of Science ®Google Scholar
• Song JY, Noh JY, Lee JS, Wie SH, Kim YK, Lee J, Jeong HW, Kim SW, Lee SH, Park K-H, et al. Effectiveness of influenza and pneumococcal polysaccharide vaccines against influenza-related outcomes including pneumonia and acute exacerbation of cardiopulmonary diseases: analysis by dominant viral subtype and vaccine matching. PLoS One. 2018;13:e0207918. doi:10.1371/journal.pone.0207918.
   PubMed Web of Science ®Google Scholar
• Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis. Vaccine. 2021;39(Suppl 1):A24–a35. doi:10.1016/j.vaccine.2020.09.004.
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, Cho GJ, Hwang TG, Kim WJ. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine. 2010;28:3929–35. doi:10.1016/j.vaccine.2010.03.067.
   PubMed Web of Science ®Google Scholar
• Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: a phase 3 randomized clinical trial. Vaccine. 2019;37:5825–34. doi:10.1016/j.vaccine.2019.08.016.
   PubMed Web of Science ®Google Scholar
• Bianculli PM, Bellier L, Mangado IO, Pérez CG, Mieres G, Lazarov L, Petitjean A, Dibarboure H, Lopez JG. Switching from trivalent to quadrivalent inactivated influenza vaccines in uruguay: a cost-effectiveness analysis. Hum. Vaccines Immunother. 2022;18(5):2050653. doi:10.1080/21645515.2022.2050653.
   PubMed Web of Science ®Google Scholar
• Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum. Vaccines Immunother. 2014;10(5):1171–80. doi:10.4161/hv.28221.
   PubMed Web of Science ®Google Scholar
• Walker DG, Hutubessy R, Beutels P. WHO guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010;28(11):2356–59. doi:10.1016/j.vaccine.2009.06.035.
   PubMed Web of Science ®Google Scholar